Andrea Volkamer is a computational chemist and active principal investigator in the field of computer-aided drug design (CADD), with a focus on kinase targets, druggability prediction, and machine learning applications. She has published extensively in journals such as the Journal of Chemical Information and Modeling and Journal of Medicinal Chemistry , with recent work up to 2025 indicating an ongoing academic research program. Her research group, referred to as 'volkamerlab,' develops open-source tools including DoGSite, KiSSim, KinFragLib, and TeachOpenCADD, which are widely used in both academic and industrial drug discovery settings. Her research interests span computational drug discovery , structural bioinformatics , kinase inhibitor design , off-target and polypharmacology prediction , and educational platforms for CADD . She emphasizes open science and reproducibility, particularly through the TeachOpenCADD initiative, which provides interactive Jupyter Notebooks and KNIME workflows for teaching cheminformatics concepts. The 15 most recent publications reflect a strong trend toward integrating machine learning and deep learning (e.g., transformers, graph neural networks) with structure-based methods such as molecular docking, free energy calculations, and binding site comparison. Her work increasingly addresses real-world challenges in drug discovery, including kinase mutation resistance, selectivity optimization, and in vivo toxicity prediction using conformal and hybrid models. Scientific Contributions and Awards: Development of key computational tools: DoGSite, KiSSim, KinFragLib, TeachOpenCADD. Leadership in open-source and open-education initiatives in cheminformatics. Active publication record in top-tier journals with interdisciplinary impact. Advising and Grants: While specific student names and grant details are not mentioned in the provided text, her role as a corresponding author on numerous publications and the existence of a dedicated research lab ('volkamerlab') imply that she mentors students and postdoctoral researchers. She likely secures competitive funding to support her research in computational drug discovery and method development. Labs and Teams: She leads the Volkamer Lab ('volkamerlab'), which focuses on developing and applying computational methods for drug discovery. The lab collaborates with both academic and pharmaceutical partners and emphasizes open-source software development and educational outreach.
